Stocks · News reference

BriaCell Therapeutics Advances Bria-MEL+ Whole Cell Melanoma Immunotherapy Vaccine Candidate Toward Clinical Development With Key Genetic Engineering Milestone

Aug 24, 2026, 11:33 AMBenzinga Newsdesk

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

BenzingaAug 5, 2026, 11:33 AMBenzinga Newsdesk
BriaCell Therapeutics Receives FDA Clearance To Proceed With Clinical Evaluation Of Bria-PROS+, Its Next-Gen Personalized Off-The-Shelf Immunotherapy For Prostate Cancer
FDA clearance of Investigational New Drug (IND) application enables BriaCell to initiate Phase 1/2a clinical study of Bria-PROS+ in prostate cancerBria-PROS+ is BriaCell’s next generation personalized immunotherapy for
Read original at benzinga
BCTX TSX:BCT
BenzingaJul 16, 2026, 11:36 AMBenzinga Newsdesk
Odette Cancer Centre At Sunnybrook Health Sciences Centre Joined BriaCell’s Ongoing Pivotal Phase 3 Study Of Bria-IMT Plus Immune Checkpoint Inhibitor In Metastatic Breast Cancer
Sunnybrook’s Odette Cancer Centre, a world-class cancer center in Toronto, Ontario, Canada, joins BriaCell’s pivotal Phase 3 clinical trial in metastatic breast cancerBriaCell Phase 3 trial featured in Nature Medicine
Read original at benzinga
BCTX TSX:BCT
BenzingaJul 15, 2026, 11:35 AMBenzinga Newsdesk
BriaCell Therapeutics Enters Manufacturing Arrangement With FUJIFILM Biotechnologies To Support Phase 3 Clinical Development And Potential Future Commercial Supply Of Its Allogenic Cell Therapy BRIA-IMT
Bria-IMT is currently being evaluated in BriaCell’s pivotal Phase 3 study of Bria-IMT in combination with an immune checkpoint inhibitor in advanced metastatic breast cancer (ClinicalTrials.gov identifier:
Read original at benzinga
BCTX